A lack of transparency for data protection and import trade, compounded with worsening patent restrictions will ensure Argentina's appeal to foreign pharmaceutical companies in 2015 is limited. The country's troubling intellectual property regime will be particularly concerning for innovative drugmakers as the adequacy of Argentina's patent law remains questionable.
The Argentine government's intervention in pharmaceutical pricing, particularly repeated price freezes, is both heavy handed and apparently open-ended. We have previously highlighted Argentina's highly challenging environment for pharmaceutical companies,, due to the anticipated future currency devaluation, high inflation and nationalisation approaches.
Complete the trial form to receive a free issue of Pharma and Healthcare Insight sent to your email address. The Pharma and Healthcare Insight provides you with in-depth country by country data, analysis and forecasts.
START A FREE TRIAL TODAY
STEP 2: SELECT PRODUCTS
Please select the free products you would like to trial:
Thank you for your interest in Pharma and Healthcare Insight
You will shortly receive an e-mail with link(s) to a full version of the newsletter(s) you selected. A member of our Client Services team will be in touch soon to receive your feedback on the newsletters and arrange a convenient time for a free demonstration of the full service. If your enquiry is urgent, please email our team here Thanks, BMI Research